RxDoctor Payments Data

Andrea Goldstein, MD

Gastroenterology · Flemington, NJNPI 1467653055

Payments from drug & device makers

$936in general payments, 2019–2025

Across 34 payments — averaging $27.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$305
  • Medtronic$171
  • Pfizer$152
  • Lilly USA, LLC$119
  • Johnson & Johnson$119
  • Phathom Pharmaceuticals, Inc.$57
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$89896%
  • Education$384%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)15$305
Medtronic2$171
Pfizer5$152
Lilly USA, LLC1$119
Johnson & Johnson2$119
Phathom Pharmaceuticals, Inc.8$57
Boston Scientific1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$936 in reported general payments places this provider in the 30th percentile of 701 gastroenterology providers in New Jersey.

See all gastroenterology providers in New Jersey

Medicare billing

Part B allowed, 2024
$240,595
Medicare patients
511
Services billed
4,377

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide94$75,016
XeljanzTofacitinib Citrate13$74,871
VemlidyTenofovir Alafenamide11$18,371
Mesalamine44$15,413
ClenpiqSod Picosulf/Mag Ox/Citric Ac88$15,009
Dexlansoprazole DrDexlansoprazole19$8,672
Mesalamine DrMesalamine11$7,115
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates67$4,381
Omeprazole325$3,153
Pantoprazole Sodium163$2,747
Balsalazide Disodium16$2,206
Famotidine95$1,994
Lubiprostone19$1,777
Dicyclomine Hcl96$1,770
Esomeprazole Magnesium27$792

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$305$75,01694 claims
PfizerXeljanz$152$74,87113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 701 gastroenterology providers in New Jersey.

Other gastroenterology in Flemington

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →